270 related articles for article (PubMed ID: 32843164)
1. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
[TBL] [Abstract][Full Text] [Related]
3. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
[TBL] [Abstract][Full Text] [Related]
4. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
Respir Med; 2021; 180():106311. PubMed ID: 33711782
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
[TBL] [Abstract][Full Text] [Related]
7. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma:
Gon Y; Ishii T; Lawrence D; Nikolaev I; Wang D; Sumi K; Nakamura Y
J Asthma; 2022 Aug; 59(8):1627-1637. PubMed ID: 34346266
[TBL] [Abstract][Full Text] [Related]
8. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN; Chapman KR; Kerstjens HAM; Gessner C; Sagara H; Tanase AM; Hosoe M; Pethe A; Lawrence D; Tillmann HC; D'Andrea P
J Asthma Allergy; 2023; 16():123-134. PubMed ID: 36714049
[TBL] [Abstract][Full Text] [Related]
9. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
[TBL] [Abstract][Full Text] [Related]
11. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
[TBL] [Abstract][Full Text] [Related]
12. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K; van Zyl-Smit R; Maspero J; Kerstjens HAM; Gon Y; Hosoe M; Tanase AM; Pethe A; Shu X; D'Andrea P
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34452934
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.
Mtibaa M; Gupta S; Muthukumar M; Marvel J; Kaur H; Ishikawa R; Olivenstein R
Clinicoecon Outcomes Res; 2021; 13():957-967. PubMed ID: 34887668
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
Mangia PP; Gallo O; Ritrovato D; Pradelli L
Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
[TBL] [Abstract][Full Text] [Related]
17. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Frith PA; Thompson PJ; Ratnavadivel R; Chang CL; Bremner P; Day P; Frenzel C; Kurstjens N;
Thorax; 2015 Jun; 70(6):519-27. PubMed ID: 25841237
[TBL] [Abstract][Full Text] [Related]
18. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
[TBL] [Abstract][Full Text] [Related]
20. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
Buhl R; Nikolaev I; Tillmann HC; Vaidya S; Bartels C; Jain M; Jauernig J; Kerstjens HAM
Pulm Pharmacol Ther; 2021 Oct; 70():102068. PubMed ID: 34329722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]